Receptor tyrosine kinase (RTK) inhibitors are among the novel adjuvant therapeutic option for several tumors including endometrial cancer for their important roles in cellular signaling, determining key roles in diverse biological processes like growth, differentiation, metabolism, and apoptosis in response to external and internal stimuli.